How Dalton Scaled A Sterile Fill-Finish Program 4× Without Adding Unnecessary Complexity Or Cost

Scaling up sterile fill-finish operations requires balancing immediate clinical timelines with future manufacturing demands. When clinical programs advance, expanding batch sizes by fourfold often presents operational friction, including costly capital investments, extensive cleaning validations, and extended qualification delays.

Transitioning from traditional glass formulation vessels to single-use formulation systems offers a strategic alternative for pharmaceutical manufacturing. Evaluating operational trade-offs early allows teams to boost production capacity without introducing unnecessary operational complexity. Adopting flexible, single-use technology minimizes capital expenditure, streamlines equipment turnaround times, and simplifies cleaning requirements, all while maintaining rigorous quality standards and supporting aggressive timelines.

View the full case study to discover how a tailored manufacturing strategy can seamlessly scale your sterile fill-finish program without adding unnecessary cost or complexity.